Which has better valuation & earnings, VRCA or PLRZ?

Polyrizon has lower revenue, but higher earnings than Verrica Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Verrica Pharmaceuticals $35.58M 2.75 -$17.89M -$1.67 N/A Polyrizon N/A N/A -$3.34M N/A N/A

Do analysts recommend PLRZ or DWTX?

Dogwood Therapeutics has a consensus price target of $12.00, indicating a potential upside of 352.83%. Given Dogwood Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Dogwood Therapeutics is more favorable than Polyrizon. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Polyrizon 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Dogwood Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger valuation & earnings, PLRZ or DWTX?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Polyrizon N/A N/A -$3.34M N/A N/A Dogwood Therapeutics N/A N/A -$34.26M -$8.95 N/A

Is PLRZ or DWTX more profitable?

Polyrizon's return on equity of 0.00% beat Dogwood Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Polyrizon N/A N/A N/A Dogwood Therapeutics N/A -75.55% -40.28%

Do analysts recommend CING or PLRZ?

Cingulate currently has a consensus price target of $27.00, indicating a potential upside of 407.52%. Given Cingulate's stronger consensus rating and higher probable upside, analysts clearly believe Cingulate is more favorable than Polyrizon. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cingulate 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Polyrizon 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, CING or PLRZ?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cingulate N/A N/A -$22.45M -$3.59 N/A Polyrizon N/A N/A -$3.34M N/A N/A

Is CING or PLRZ more profitable?

Polyrizon's return on equity of 0.00% beat Cingulate's return on equity. Company Net Margins Return on Equity Return on Assets Cingulate N/A -238.40% -128.67% Polyrizon N/A N/A N/A

Do analysts prefer PLRZ or LONA?

Athira Pharma has a consensus target price of $17.33, indicating a potential upside of 118.30%. Given Athira Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Athira Pharma is more favorable than Polyrizon. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Polyrizon 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Athira Pharma 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has preferable valuation & earnings, PLRZ or LONA?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Polyrizon N/A N/A -$3.34M N/A N/A Athira Pharma N/A N/A -$105.61M -$4.21 N/A

Is PLRZ or LONA more profitable?

Polyrizon's return on equity of 0.00% beat Athira Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Polyrizon N/A N/A N/A Athira Pharma N/A -411.58% -225.73%

Do analysts prefer PLRZ or SPRO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Polyrizon 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Spero Therapeutics 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better earnings & valuation, PLRZ or SPRO?

Spero Therapeutics has higher revenue and earnings than Polyrizon. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Polyrizon N/A N/A -$3.34M N/A N/A Spero Therapeutics $66.80M 1.05 $8.57M $0.11 10.91

Polyrizon (PLRZ) Competitors

$13.15 +0.35 (+2.73%)

As of 08/28/2026 04:00 PM Eastern

Compare

PLRZ vs. VRCA, DWTX, CING, LONA, and SPRO

Should you buy Polyrizon stock or one of its competitors? Polyrizon's main competitors and comparable companies include Verrica Pharmaceuticals (VRCA), Dogwood Therapeutics (DWTX), Cingulate (CING), Athira Pharma (LONA), and Spero Therapeutics (SPRO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Polyrizon compare to Verrica Pharmaceuticals?

Verrica Pharmaceuticals (NASDAQ:VRCA) and Polyrizon (NASDAQ:PLRZ) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

Polyrizon has lower revenue, but higher earnings than Verrica Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verrica Pharmaceuticals	$35.58M	2.75	-$17.89M	-$1.67	N/A
Polyrizon	N/A	N/A	-$3.34M	N/A	N/A

Polyrizon has a net margin of 0.00% compared to Verrica Pharmaceuticals' net margin of -102.84%. Polyrizon's return on equity of 0.00% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verrica Pharmaceuticals	-102.84%	-407.11%	-70.17%
Polyrizon	N/A	N/A	N/A

42.5% of Verrica Pharmaceuticals shares are held by institutional investors. 52.9% of Verrica Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Verrica Pharmaceuticals had 5 more articles in the media than Polyrizon. MarketBeat recorded 7 mentions for Verrica Pharmaceuticals and 2 mentions for Polyrizon. Polyrizon's average media sentiment score of 0.43 beat Verrica Pharmaceuticals' score of 0.41 indicating that Polyrizon is being referred to more favorably in the news media.

Company	Overall Sentiment
Verrica Pharmaceuticals	Neutral
Polyrizon	Neutral

Verrica Pharmaceuticals currently has a consensus target price of $12.67, suggesting a potential upside of 122.61%. Given Verrica Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Verrica Pharmaceuticals is more favorable than Polyrizon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Polyrizon	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Verrica Pharmaceuticals has a beta of 1.49, meaning that its share price is 49% more volatile than the broader market. Comparatively, Polyrizon has a beta of -1.5, meaning that its share price is 250% less volatile than the broader market.

Summary

Verrica Pharmaceuticals beats Polyrizon on 8 of the 13 factors compared between the two stocks.

How does Polyrizon compare to Dogwood Therapeutics?

Polyrizon (NASDAQ:PLRZ) and Dogwood Therapeutics (NASDAQ:DWTX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, earnings and risk.

Dogwood Therapeutics has a consensus price target of $12.00, indicating a potential upside of 352.83%. Given Dogwood Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Dogwood Therapeutics is more favorable than Polyrizon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polyrizon	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Dogwood Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polyrizon	N/A	N/A	-$3.34M	N/A	N/A
Dogwood Therapeutics	N/A	N/A	-$34.26M	-$8.95	N/A

Polyrizon's return on equity of 0.00% beat Dogwood Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Polyrizon	N/A	N/A	N/A
Dogwood Therapeutics	N/A	-75.55%	-40.28%

Polyrizon has a beta of -1.5, meaning that its share price is 250% less volatile than the broader market. Comparatively, Dogwood Therapeutics has a beta of 1.71, meaning that its share price is 71% more volatile than the broader market.

9.1% of Dogwood Therapeutics shares are held by institutional investors. 0.3% of Dogwood Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Polyrizon and Polyrizon both had 2 articles in the media. Dogwood Therapeutics' average media sentiment score of 0.96 beat Polyrizon's score of 0.43 indicating that Dogwood Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Polyrizon	Neutral
Dogwood Therapeutics	Positive

Summary

Dogwood Therapeutics beats Polyrizon on 7 of the 10 factors compared between the two stocks.

How does Polyrizon compare to Cingulate?

Cingulate (NASDAQ:CING) and Polyrizon (NASDAQ:PLRZ) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, media sentiment, earnings and valuation.

In the previous week, Cingulate had 9 more articles in the media than Polyrizon. MarketBeat recorded 11 mentions for Cingulate and 2 mentions for Polyrizon. Polyrizon's average media sentiment score of 0.43 beat Cingulate's score of -0.24 indicating that Polyrizon is being referred to more favorably in the news media.

Company	Overall Sentiment
Cingulate	Neutral
Polyrizon	Neutral

41.3% of Cingulate shares are owned by institutional investors. 5.3% of Cingulate shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Cingulate has a beta of -0.9, suggesting that its stock price is 190% less volatile than the broader market. Comparatively, Polyrizon has a beta of -1.5, suggesting that its stock price is 250% less volatile than the broader market.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cingulate	N/A	N/A	-$22.45M	-$3.59	N/A
Polyrizon	N/A	N/A	-$3.34M	N/A	N/A

Polyrizon's return on equity of 0.00% beat Cingulate's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cingulate	N/A	-238.40%	-128.67%
Polyrizon	N/A	N/A	N/A

Cingulate currently has a consensus price target of $27.00, indicating a potential upside of 407.52%. Given Cingulate's stronger consensus rating and higher probable upside, analysts clearly believe Cingulate is more favorable than Polyrizon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cingulate	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Polyrizon	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Cingulate beats Polyrizon on 7 of the 11 factors compared between the two stocks.

How does Polyrizon compare to Athira Pharma?

Polyrizon (NASDAQ:PLRZ) and Athira Pharma (NASDAQ:LONA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, dividends, risk, earnings, media sentiment and valuation.

Polyrizon's return on equity of 0.00% beat Athira Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Polyrizon	N/A	N/A	N/A
Athira Pharma	N/A	-411.58%	-225.73%

In the previous week, Polyrizon had 1 more articles in the media than Athira Pharma. MarketBeat recorded 2 mentions for Polyrizon and 1 mentions for Athira Pharma. Athira Pharma's average media sentiment score of 1.89 beat Polyrizon's score of 0.43 indicating that Athira Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Polyrizon	Neutral
Athira Pharma	Very Positive

Polyrizon has a beta of -1.5, meaning that its stock price is 250% less volatile than the broader market. Comparatively, Athira Pharma has a beta of 2.05, meaning that its stock price is 105% more volatile than the broader market.

Athira Pharma has a consensus target price of $17.33, indicating a potential upside of 118.30%. Given Athira Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Athira Pharma is more favorable than Polyrizon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polyrizon	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Athira Pharma	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

57.1% of Athira Pharma shares are held by institutional investors. 25.7% of Athira Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polyrizon	N/A	N/A	-$3.34M	N/A	N/A
Athira Pharma	N/A	N/A	-$105.61M	-$4.21	N/A

Summary

Athira Pharma beats Polyrizon on 7 of the 11 factors compared between the two stocks.

How does Polyrizon compare to Spero Therapeutics?

Polyrizon (NASDAQ:PLRZ) and Spero Therapeutics (NASDAQ:SPRO) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings, media sentiment and analyst recommendations.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polyrizon	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Spero Therapeutics	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Polyrizon has a beta of -1.5, suggesting that its share price is 250% less volatile than the broader market. Comparatively, Spero Therapeutics has a beta of 1.55, suggesting that its share price is 55% more volatile than the broader market.

In the previous week, Polyrizon had 1 more articles in the media than Spero Therapeutics. MarketBeat recorded 2 mentions for Polyrizon and 1 mentions for Spero Therapeutics. Spero Therapeutics' average media sentiment score of 0.94 beat Polyrizon's score of 0.43 indicating that Spero Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Polyrizon	Neutral
Spero Therapeutics	Positive

Spero Therapeutics has a net margin of 24.90% compared to Polyrizon's net margin of 0.00%. Spero Therapeutics' return on equity of 16.17% beat Polyrizon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Polyrizon	N/A	N/A	N/A
Spero Therapeutics	24.90%	16.17%	12.57%

Spero Therapeutics has higher revenue and earnings than Polyrizon.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polyrizon	N/A	N/A	-$3.34M	N/A	N/A
Spero Therapeutics	$66.80M	1.05	$8.57M	$0.11	10.91

25.6% of Spero Therapeutics shares are owned by institutional investors. 2.9% of Spero Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Spero Therapeutics beats Polyrizon on 10 of the 11 factors compared between the two stocks.

Get Polyrizon News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PLRZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PLRZ vs. The Competition

Export

Metric	Polyrizon	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$27.39M	$12.17B	$7.21B	$12.90B
Dividend Yield	N/A	2.62%	2.54%	11.28%
P/E Ratio	N/A	787.65	273.16	25.42
Price / Sales	N/A	755.84	630.81	94.42
Price / Cash	N/A	15.32	28.74	36.03
Price / Book	1.01	10.49	11.08	6.36
Net Income	-$3.34M	$2.83B	$3.48B	$349.79M
7 Day Performance	27.67%	0.39%	0.13%	-0.80%
1 Month Performance	13.17%	5.34%	7.08%	4.13%
1 Year Performance	101.07%	6.05%	24.67%	15.17%

Polyrizon Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PLRZ Polyrizon	0.2716 of 5 stars	$13.15 +2.7%	N/A	+101.1%	$27.39M	N/A	N/A	N/A	Short Interest Increase
VRCA Verrica Pharmaceuticals	4.1842 of 5 stars	$4.89 +0.6%	$14.50 +196.5%	+1.8%	$84.01M	$30.32M	N/A	40	News Coverage Analyst Forecast
DWTX Dogwood Therapeutics	2.4332 of 5 stars	$2.46 +5.6%	$12.00 +387.8%	-46.6%	$83.62M	N/A	N/A	5	Short Interest Decrease
CING Cingulate	2.5554 of 5 stars	$5.50 +3.2%	$27.33 +397.0%	+33.3%	$79.97M	N/A	N/A	20	News Coverage Analyst Upgrade Analyst Revision
LONA Athira Pharma	3.7819 of 5 stars	$7.74 +0.5%	$17.33 +123.9%	N/A	$72.71M	N/A	N/A	40	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PLRZ) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Polyrizon (PLRZ) Competitors

PLRZ vs. VRCA, DWTX, CING, LONA, and SPRO

How does Polyrizon compare to Verrica Pharmaceuticals?

Summary

How does Polyrizon compare to Dogwood Therapeutics?

Summary

How does Polyrizon compare to Cingulate?

Summary

How does Polyrizon compare to Athira Pharma?

Summary

How does Polyrizon compare to Spero Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLRZ vs. The Competition

Polyrizon Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Polyrizon (PLRZ) Competitors

PLRZ vs. VRCA, DWTX, CING, LONA, and SPRO

How does Polyrizon compare to Verrica Pharmaceuticals?

Which has better valuation & earnings, VRCA or PLRZ?

Is VRCA or PLRZ more profitable?

Do institutionals and insiders hold more shares of VRCA or PLRZ?

Does the media prefer VRCA or PLRZ?

Do analysts recommend VRCA or PLRZ?

Which has more risk & volatility, VRCA or PLRZ?

Summary

How does Polyrizon compare to Dogwood Therapeutics?

Do analysts recommend PLRZ or DWTX?

Which has stronger valuation & earnings, PLRZ or DWTX?

Is PLRZ or DWTX more profitable?

Which has more volatility and risk, PLRZ or DWTX?

Do institutionals and insiders believe in PLRZ or DWTX?

Does the media prefer PLRZ or DWTX?

Summary

How does Polyrizon compare to Cingulate?

Does the media refer more to CING or PLRZ?

Do insiders and institutionals have more ownership in CING or PLRZ?

Which has more risk & volatility, CING or PLRZ?

Which has preferable valuation and earnings, CING or PLRZ?

Is CING or PLRZ more profitable?

Do analysts recommend CING or PLRZ?

Summary

How does Polyrizon compare to Athira Pharma?

Is PLRZ or LONA more profitable?

Does the media favor PLRZ or LONA?

Which has more volatility and risk, PLRZ or LONA?

Do analysts prefer PLRZ or LONA?

Do insiders and institutionals believe in PLRZ or LONA?

Which has preferable valuation & earnings, PLRZ or LONA?

Summary

How does Polyrizon compare to Spero Therapeutics?

Do analysts prefer PLRZ or SPRO?

Which has more risk & volatility, PLRZ or SPRO?

Does the media prefer PLRZ or SPRO?

Is PLRZ or SPRO more profitable?

Which has better earnings & valuation, PLRZ or SPRO?

Do institutionals & insiders believe in PLRZ or SPRO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLRZ vs. The Competition

Polyrizon Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools